{"id":"generic-plerixafor","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Plerixafor blocks the CXCR4 receptor on the surface of hematopoietic stem and progenitor cells, disrupting their interaction with stromal cell-derived factor-1 (SDF-1) in the bone marrow microenvironment. This disruption causes stem cells to be released into the peripheral circulation, where they can be collected for transplantation or mobilized for therapeutic purposes. The drug is used as a mobilizing agent to enhance stem cell collection in patients undergoing autologous stem cell transplantation.","oneSentence":"Plerixafor is a CXCR4 chemokine receptor antagonist that mobilizes hematopoietic stem cells from the bone marrow into peripheral blood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:22.999Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mobilization of hematopoietic stem cells to peripheral blood for collection and autologous transplantation in patients with non-Hodgkin lymphoma or multiple myeloma"}]},"trialDetails":[{"nctId":"NCT06892119","phase":"PHASE1","title":"Generic Plerixafor Efficacy of Autologous Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Hospital Universitario Dr. Jose E. Gonzalez","startDate":"2019-12-09","conditions":"Lymphoma, Myeloma","enrollment":6},{"nctId":"NCT00838357","phase":"PHASE3","title":"A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2008-09","conditions":"Lymphoma (Non-Hodgkin's Lymphoma), Hodgkin's Disease or Multiple Myeloma, Front Line Mobilization","enrollment":118}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Generic = Plerixafor","genericName":"Generic = Plerixafor","companyName":"Genzyme, a Sanofi Company","companyId":"genzyme-a-sanofi-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Plerixafor is a CXCR4 chemokine receptor antagonist that mobilizes hematopoietic stem cells from the bone marrow into peripheral blood. Used for Mobilization of hematopoietic stem cells to peripheral blood for collection and autologous transplantation in patients with non-Hodgkin lymphoma or multiple myeloma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}